VALIDATION OF LST EUROFLOW
(Abstract release date: 05/19/16)
EHA Library. Berkovits A. 06/09/16; 134943; PB2043
Dr. Alejandro Berkovits
Contributions
Contributions
Abstract
Abstract: PB2043
Type: Publication Only
Background
Immunophenotype analysis by multiparametric flow cytometry (MFC) is an important tool, together with pathology, cytogenetical and molecular analysis, for the diagnosis, classification and treatment monitoring of hematological malignancies. The accurate identification of abnormal lymphocytes by MFC requires a unique standardized combination of fluorochrome-conjugated antibodies. The international consortium of standardization, Euroflow®, elaborated a lymphoproliferative disease screening panel (LST) aiming the identification of normal or aberrant B, T or NK lymphocytes in different tissues.
Aims
Confirm that the screening of lympholiferative disease using MFC analysis with LST Euroflow® panel, in an accurate method to recognize, quantify and characterize abnormal lymphocyte populations in lymphoma positive tissue biopsies in Chilean population.
Methods
Retrospective analysis of tissue and / or bone marrow samples sent simultaneously to both the pathology laboratory for biopsy (reviewed by only one expert hematopathology of our institution) and to immunology section of Clinica Alemana de Santiago for immunophenotyping analysis, since the implementation of LST Euroflow® protocol for lymphoproliferative disease screening. All tissues were processed in 8 colors FACSCanto cytometer by BD Bioscience II. The panels and fluorochromes used in every analysis were: CD4 and CD20 in PacB, CD45 in AmCyan, CD8 and SmIgl in FITC, CD56 and SmIgk in PE, CD5 in PerCPCy5.5, CD19 and TCRgd in PECy7, SmCD3 in APC and CD38 in APCCy7.
Results
One hundred and seventy-four samples with suspect of lymphoproliferative disease and concomitant pathology report in our institution were revised from June 2013 to December 2015. Exclusion criteria included Hodgkin Lymphoma and non-hematological neoplastic diagnosis by histology (14 and 11 tissues samples respectively). Fifty tissues were positive for lymphoproliferative disease by biopsy, including 16 follicular lymphomas, 12 diffuse large B cell lymphomas, 7 SLL/CLL, 5 mantle cell lymphomas, 3 lymphoplasmocytic lymphomas, 3 marginal zone lymphomas, 2 Hairy cell leukemia, 1 T gamma-delta lymphoma and 1 multiple myeloma. The screening analysis by MFC using LST panel showed abnormal and/or clonal population in 100% of positive lymphoproliferative disease biopsies. In the analysis of the non-neoplastic histological biopsies (87 samples), MFC detected subclinical clonal or abnormal lymphocytic population in 10 cases, being both negatives in 77. The sensitivity, specificity, positive predictive value and negative predictive value of LST for diagnosis of lymphoproliferative disease was 100%, 89%, 86% and 100% respectively.
Conclusion
Lymphoproliferative panel LST is an effective screening tool for lymphoma diagnosis in Chilean population in different tissues including bone marrow.
Session topic: E-poster
Keyword(s): Diagnosis, Flow cytometry, Lymphoma
Type: Publication Only
Background
Immunophenotype analysis by multiparametric flow cytometry (MFC) is an important tool, together with pathology, cytogenetical and molecular analysis, for the diagnosis, classification and treatment monitoring of hematological malignancies. The accurate identification of abnormal lymphocytes by MFC requires a unique standardized combination of fluorochrome-conjugated antibodies. The international consortium of standardization, Euroflow®, elaborated a lymphoproliferative disease screening panel (LST) aiming the identification of normal or aberrant B, T or NK lymphocytes in different tissues.
Aims
Confirm that the screening of lympholiferative disease using MFC analysis with LST Euroflow® panel, in an accurate method to recognize, quantify and characterize abnormal lymphocyte populations in lymphoma positive tissue biopsies in Chilean population.
Methods
Retrospective analysis of tissue and / or bone marrow samples sent simultaneously to both the pathology laboratory for biopsy (reviewed by only one expert hematopathology of our institution) and to immunology section of Clinica Alemana de Santiago for immunophenotyping analysis, since the implementation of LST Euroflow® protocol for lymphoproliferative disease screening. All tissues were processed in 8 colors FACSCanto cytometer by BD Bioscience II. The panels and fluorochromes used in every analysis were: CD4 and CD20 in PacB, CD45 in AmCyan, CD8 and SmIgl in FITC, CD56 and SmIgk in PE, CD5 in PerCPCy5.5, CD19 and TCRgd in PECy7, SmCD3 in APC and CD38 in APCCy7.
Results
One hundred and seventy-four samples with suspect of lymphoproliferative disease and concomitant pathology report in our institution were revised from June 2013 to December 2015. Exclusion criteria included Hodgkin Lymphoma and non-hematological neoplastic diagnosis by histology (14 and 11 tissues samples respectively). Fifty tissues were positive for lymphoproliferative disease by biopsy, including 16 follicular lymphomas, 12 diffuse large B cell lymphomas, 7 SLL/CLL, 5 mantle cell lymphomas, 3 lymphoplasmocytic lymphomas, 3 marginal zone lymphomas, 2 Hairy cell leukemia, 1 T gamma-delta lymphoma and 1 multiple myeloma. The screening analysis by MFC using LST panel showed abnormal and/or clonal population in 100% of positive lymphoproliferative disease biopsies. In the analysis of the non-neoplastic histological biopsies (87 samples), MFC detected subclinical clonal or abnormal lymphocytic population in 10 cases, being both negatives in 77. The sensitivity, specificity, positive predictive value and negative predictive value of LST for diagnosis of lymphoproliferative disease was 100%, 89%, 86% and 100% respectively.
Conclusion
Lymphoproliferative panel LST is an effective screening tool for lymphoma diagnosis in Chilean population in different tissues including bone marrow.
Session topic: E-poster
Keyword(s): Diagnosis, Flow cytometry, Lymphoma
Abstract: PB2043
Type: Publication Only
Background
Immunophenotype analysis by multiparametric flow cytometry (MFC) is an important tool, together with pathology, cytogenetical and molecular analysis, for the diagnosis, classification and treatment monitoring of hematological malignancies. The accurate identification of abnormal lymphocytes by MFC requires a unique standardized combination of fluorochrome-conjugated antibodies. The international consortium of standardization, Euroflow®, elaborated a lymphoproliferative disease screening panel (LST) aiming the identification of normal or aberrant B, T or NK lymphocytes in different tissues.
Aims
Confirm that the screening of lympholiferative disease using MFC analysis with LST Euroflow® panel, in an accurate method to recognize, quantify and characterize abnormal lymphocyte populations in lymphoma positive tissue biopsies in Chilean population.
Methods
Retrospective analysis of tissue and / or bone marrow samples sent simultaneously to both the pathology laboratory for biopsy (reviewed by only one expert hematopathology of our institution) and to immunology section of Clinica Alemana de Santiago for immunophenotyping analysis, since the implementation of LST Euroflow® protocol for lymphoproliferative disease screening. All tissues were processed in 8 colors FACSCanto cytometer by BD Bioscience II. The panels and fluorochromes used in every analysis were: CD4 and CD20 in PacB, CD45 in AmCyan, CD8 and SmIgl in FITC, CD56 and SmIgk in PE, CD5 in PerCPCy5.5, CD19 and TCRgd in PECy7, SmCD3 in APC and CD38 in APCCy7.
Results
One hundred and seventy-four samples with suspect of lymphoproliferative disease and concomitant pathology report in our institution were revised from June 2013 to December 2015. Exclusion criteria included Hodgkin Lymphoma and non-hematological neoplastic diagnosis by histology (14 and 11 tissues samples respectively). Fifty tissues were positive for lymphoproliferative disease by biopsy, including 16 follicular lymphomas, 12 diffuse large B cell lymphomas, 7 SLL/CLL, 5 mantle cell lymphomas, 3 lymphoplasmocytic lymphomas, 3 marginal zone lymphomas, 2 Hairy cell leukemia, 1 T gamma-delta lymphoma and 1 multiple myeloma. The screening analysis by MFC using LST panel showed abnormal and/or clonal population in 100% of positive lymphoproliferative disease biopsies. In the analysis of the non-neoplastic histological biopsies (87 samples), MFC detected subclinical clonal or abnormal lymphocytic population in 10 cases, being both negatives in 77. The sensitivity, specificity, positive predictive value and negative predictive value of LST for diagnosis of lymphoproliferative disease was 100%, 89%, 86% and 100% respectively.
Conclusion
Lymphoproliferative panel LST is an effective screening tool for lymphoma diagnosis in Chilean population in different tissues including bone marrow.
Session topic: E-poster
Keyword(s): Diagnosis, Flow cytometry, Lymphoma
Type: Publication Only
Background
Immunophenotype analysis by multiparametric flow cytometry (MFC) is an important tool, together with pathology, cytogenetical and molecular analysis, for the diagnosis, classification and treatment monitoring of hematological malignancies. The accurate identification of abnormal lymphocytes by MFC requires a unique standardized combination of fluorochrome-conjugated antibodies. The international consortium of standardization, Euroflow®, elaborated a lymphoproliferative disease screening panel (LST) aiming the identification of normal or aberrant B, T or NK lymphocytes in different tissues.
Aims
Confirm that the screening of lympholiferative disease using MFC analysis with LST Euroflow® panel, in an accurate method to recognize, quantify and characterize abnormal lymphocyte populations in lymphoma positive tissue biopsies in Chilean population.
Methods
Retrospective analysis of tissue and / or bone marrow samples sent simultaneously to both the pathology laboratory for biopsy (reviewed by only one expert hematopathology of our institution) and to immunology section of Clinica Alemana de Santiago for immunophenotyping analysis, since the implementation of LST Euroflow® protocol for lymphoproliferative disease screening. All tissues were processed in 8 colors FACSCanto cytometer by BD Bioscience II. The panels and fluorochromes used in every analysis were: CD4 and CD20 in PacB, CD45 in AmCyan, CD8 and SmIgl in FITC, CD56 and SmIgk in PE, CD5 in PerCPCy5.5, CD19 and TCRgd in PECy7, SmCD3 in APC and CD38 in APCCy7.
Results
One hundred and seventy-four samples with suspect of lymphoproliferative disease and concomitant pathology report in our institution were revised from June 2013 to December 2015. Exclusion criteria included Hodgkin Lymphoma and non-hematological neoplastic diagnosis by histology (14 and 11 tissues samples respectively). Fifty tissues were positive for lymphoproliferative disease by biopsy, including 16 follicular lymphomas, 12 diffuse large B cell lymphomas, 7 SLL/CLL, 5 mantle cell lymphomas, 3 lymphoplasmocytic lymphomas, 3 marginal zone lymphomas, 2 Hairy cell leukemia, 1 T gamma-delta lymphoma and 1 multiple myeloma. The screening analysis by MFC using LST panel showed abnormal and/or clonal population in 100% of positive lymphoproliferative disease biopsies. In the analysis of the non-neoplastic histological biopsies (87 samples), MFC detected subclinical clonal or abnormal lymphocytic population in 10 cases, being both negatives in 77. The sensitivity, specificity, positive predictive value and negative predictive value of LST for diagnosis of lymphoproliferative disease was 100%, 89%, 86% and 100% respectively.
Conclusion
Lymphoproliferative panel LST is an effective screening tool for lymphoma diagnosis in Chilean population in different tissues including bone marrow.
Session topic: E-poster
Keyword(s): Diagnosis, Flow cytometry, Lymphoma
{{ help_message }}
{{filter}}